Verastem Stock
Verastem, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Daniel W. Paterson
- Employees
- 102
- Market cap
- $783 M
- IPO
- 27/01/2012
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the…
Verastem stock: price history
1D
-6.3%
1W
+3.2%
1M
+18.2%
6M
+31.5%
YTD
+12.0%
1Y
-9.0%
2Y
+159.8%
5Y
-73.9%
10Y
-47.4%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~2% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 15/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BullishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Verastem
Analyst assessment of Verastem
PRICE TARGET LOW
US$12.00
CONSENSUS
US$16.43
MEDIAN
US$18.00
PRICE TARGET HIGH
US$22.00
0
STRONG BUY
15
BUY
4
HOLD
0
SELL
0
STRONG SELL
19
TOTAL · Buy
As of: 15/10/2026
Verastem stock metrics
P/E
-3.52
P/B
17.32
EV/EBITDA
-3.66
RETURN ON EQUITY
-69.4%
NET MARGIN
-86.5%
DEBT/EQUITY
1.69
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
77.8%
FLOAT SHARES
70,500,922
AVG. DAILY VOLUME (30D)
4,207,783
Insider transactions (SEC)
Calkins Daniel
Paterson Dan
Paterson Dan
Calkins Daniel
Calkins Daniel
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -6.3%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Verastem stock
What does Verastem do?
Verastem, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Daniel W. Paterson, the company employs around 102 people.
The IPO was on 27/01/2012; the stock trades on NASDAQ under the ticker VSTM.
What do analysts say about Verastem stock?
19 analysts rate the stock, the consensus is Buy (as of 15/10/2026).
The average price target is US$16.43, ranging from US$12.00 to US$22.00, with a median of US$18.00.
This is an external assessment, not a statement by Market Jury.
When does Verastem report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly -2% stronger than usual.
Does Verastem pay a dividend?
No, Verastem currently does not pay a dividend.
Which stocks are comparable to Verastem?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Verastem stock analyzed?
Clicking "Analyze stock" lets five strategies assess Verastem against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.